Pfizer Subsidiary, Wyeth LLC, to Redeem 5.500% Notes Due March 15, 2013

  Pfizer Subsidiary, Wyeth LLC, to Redeem 5.500% Notes Due March 15, 2013

Business Wire

NEW YORK -- November 26, 2012

Pfizer Inc. (NYSE: PFE) today announced that Wyeth LLC, its wholly-owned
subsidiary, has notified The Bank of New York Mellon, as trustee under the
applicable indenture, of its election to fully redeem all of its outstanding
5.500% Notes due March 15, 2013 (after giving effect to a December 4, 2003
upward interest rate adjustment of 0.25%) (CUSIP No. 983024AA8) (the “Notes”).
The aggregate principal amount of Notes currently outstanding is $1.5 billion.
The redemption date for the Notes will be December 26, 2012 (the “Redemption
Date”).

The redemption price (“Redemption Price”) for the Notes will be a price equal
to the greater of (i) 100% of the principal amount of the Notes, or (ii) the
sum, as determined by the Quotation Agent (as defined in the Global Note, the
form of which was filed with the Securities and Exchange Commission as part of
Exhibit 4.4 to Wyeth’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2002 (File No. 001-01225) (the “Global Note”)), of the present
value of the principal amount of the Notes and the remaining scheduled
payments of interest on the Notes from the Redemption Date to the maturity
date of the Notes, exclusive of interest accrued to the Redemption Date,
discounted from their respective scheduled payment dates to the Redemption
Date on a semiannual basis (assuming a 360-day year of twelve 30-day months)
at the Treasury Rate (as defined in the Global Note) plus 25 basis points, in
each case plus accrued and unpaid interest on the principal amount being
redeemed to (but excluding) the Redemption Date.

On and after the Redemption Date, the Redemption Price will become due and
payable in respect of the Notes, and interest on the Notes will cease to
accrue on and after such date.

Notice of the redemption of the Notes (the “Notice of Redemption”) is expected
to be mailed on November 26, 2012. The redemption will be effected in
accordance with the applicable terms of the indenture under which the Notes
were issued.

The paying agent for the redemption is The Bank of New York Mellon. The
relevant contact information for The Bank of New York Mellon is set forth in
the Notice of Redemption.

This announcement is neither an offer to sell nor a solicitation of an offer
to buy any of the Notes and shall not constitute an offer, solicitation or
sale in any jurisdiction in which such offer, solicitation or sale is
unlawful.

Pfizer Inc: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and
well-being at every stage of life. We strive to set the standard for quality,
safety and value in the discovery, development and manufacturing of medicines
for people and animals. Our diversified global health care portfolio includes
human and animal biologic and small molecule medicines and vaccines, as well
as nutritional products and many of the world’s best-known consumer products.
Every day, Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge the most
feared diseases of our time. Consistent with our responsibility as the world’s
leading biopharmaceutical company, we also collaborate with health care
providers, governments and local communities to support and expand access to
reliable, affordable health care around the world. For more than 150 years,
Pfizer has worked to make a difference for all who rely on us. To learn more
about our commitments, please visit us at www.pfizer.com.

Contact:

Media:
Pfizer
Joan Campion, 212-733-2798
or
Investors:
Pfizer
Suzanne Harnett, 212-733-8009